trial · primary record
Macitentan
Hypertension, Pulmonary
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 280 |
| Primary completion | 2033-09-28 |
| Primary endpoint | Frequency of Treatment Emergent Adverse Events (TEAEs) |
| Registry ID | NCT05179876 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:55.927Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05179876
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Macitentan · approval
- Macitentan · compound